Platinum-based chemotherapeutic drugs such as carboplatin, cisplatin, and oxaliplatin have also been shown to reduce PD-L2 expression on tumor cells, resulting in increased tumor cell recognition, proliferation and cytokine secretion of tumor-specific T cells (44) (Figure 1B). Here, PDCD1LG2 is linked to neoplasm.